Medtronic
(MDT) ✕
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
undefined
undefined%
At close: undefined
79.83
0.10%
Pre-market Jan 07, 2025, 04:01 AM EST
Medtronic Revenue Breakdown
Quarter | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | Apr 27, 2018 | Jan 26, 2018 | Oct 27, 2017 | Jul 28, 2017 | Apr 28, 2017 | Jan 27, 2017 | Oct 28, 2016 | Jul 29, 2016 | Apr 29, 2016 | Jan 29, 2016 | Oct 30, 2015 | Jul 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardiac and Vascular Group Revenue | 3.10B | 3.01B | 6.06B | 963.00M | 578.00M | 3.31B | 570.00M | 556.00M | 541.00M | 2.96B | 584.00M | 585.00M | 572.00M | 2.71B | 2.73B | 2.43B | 2.00B | 2.82B | 2.85B | 2.79B | 3.05B | 2.79B | 2.86B | 2.81B | 3.13B | 2.80B | 2.77B | 2.65B | 2.85B | 2.55B | 2.58B | 2.52B | 2.74B | 2.41B | 2.48B | 2.57B |
Cardiac and Vascular Group Revenue Growth | +3.16% | -50.36% | +529.08% | +66.61% | -82.56% | +481.58% | +2.52% | +2.77% | -81.73% | +407.02% | -0.17% | +2.27% | -78.87% | -0.66% | +12.00% | +21.41% | -28.91% | -1.26% | +2.33% | -8.52% | +9.48% | -2.52% | +1.67% | -10.33% | +11.96% | +0.97% | +4.80% | -7.09% | +11.77% | -1.39% | +2.62% | -8.00% | +13.57% | -2.90% | -3.31% | n/a |
Diabetes Group Revenue | 686.00M | 647.00M | 947.00M | 2.14B | 2.04B | 595.00M | 2.14B | 2.07B | 2.00B | 597.00M | 2.29B | 2.30B | 2.32B | 630.00M | 574.00M | 562.00M | 570.00M | 610.00M | 596.00M | 592.00M | 626.00M | 610.00M | 583.00M | 572.00M | 645.00M | 584.00M | 462.00M | 449.00M | 512.00M | 501.00M | 462.00M | 452.00M | 495.00M | 474.00M | 450.00M | 445.00M |
Diabetes Group Revenue Growth | +6.03% | -31.68% | -55.79% | +5.05% | +242.69% | -72.16% | +3.24% | +3.45% | +235.18% | -73.93% | -0.39% | -0.99% | +268.57% | +9.76% | +2.14% | -1.40% | -6.56% | +2.35% | +0.68% | -5.43% | +2.62% | +4.63% | +1.92% | -11.32% | +10.45% | +26.41% | +2.90% | -12.30% | +2.20% | +8.44% | +2.21% | -8.69% | +4.43% | +5.33% | +1.12% | n/a |
Medical Surgical Revenue | 2.13B | 2.00B | 4.24B | 2.29B | 2.22B | 2.23B | 2.25B | 2.19B | 2.12B | 2.23B | 2.14B | 2.14B | 2.20B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Medical Surgical Revenue Growth | +6.61% | -52.88% | +85.14% | +3.11% | -0.27% | -1.02% | +2.84% | +3.36% | -5.16% | +4.01% | +0.37% | -3.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Neuroscience Group Revenue | 2.45B | 2.32B | 4.90B | n/a | n/a | 2.41B | n/a | n/a | n/a | 2.30B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Neuroscience Group Revenue Growth | +5.78% | -52.70% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
Quarter | Apr 26, 2024 | Apr 28, 2023 | Apr 29, 2022 | Apr 30, 2021 | Apr 24, 2020 | Apr 26, 2019 |
---|---|---|---|---|---|---|
Japan, Australia, New Zealand, Korea, Canada, And Western Europe Revenue | 9.98B | 9.41B | 10.13B | 9.81B | 9.29B | 9.63B |
Japan, Australia, New Zealand, Korea, Canada, And Western Europe Revenue Growth | +6.07% | -7.09% | +3.17% | +5.69% | -3.57% | n/a |
Middle East, Africa, Latin America, Eastern Europe, And Asia, Excluding Japan And Korea Revenue | 5.82B | 5.45B | 5.43B | 4.78B | 4.71B | 4.73B |
Middle East, Africa, Latin America, Eastern Europe, And Asia, Excluding Japan And Korea Revenue Growth | +6.92% | +0.37% | +13.59% | +1.49% | -0.53% | n/a |
Operating Expense Breakdown
Quarter | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | Apr 26, 2019 | Jan 25, 2019 | Oct 26, 2018 | Jul 27, 2018 | Apr 27, 2018 | Jan 26, 2018 | Oct 27, 2017 | Jul 28, 2017 | Apr 28, 2017 | Jan 27, 2017 | Oct 28, 2016 | Jul 29, 2016 | Apr 29, 2016 | Jan 29, 2016 | Oct 30, 2015 | Jul 31, 2015 | Apr 24, 2015 | Jan 23, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 2.76B | 2.63B | 2.73B | 2.67B | 2.69B | 2.61B | 2.62B | 2.62B | 2.62B | 2.54B | 2.52B | 2.56B | 2.62B | 2.55B | 2.59B | 2.54B | 2.60B | 2.42B | 2.36B | 2.59B | 2.62B | 2.54B | 2.62B | 2.60B | 2.60B | 2.60B | 2.55B | 2.50B | 2.44B | 2.48B | 2.48B | 2.39B | 2.42B | 2.43B | 2.36B | 2.32B | 2.34B | 2.45B | 2.40B | 1.49B |
Selling, General, and Administrative Revenue Growth | +4.99% | -3.84% | +2.17% | -0.48% | +2.79% | -0.11% | +0.04% | -0.08% | +3.07% | +0.55% | -1.41% | -2.07% | +2.67% | -1.81% | +2.25% | -2.42% | +7.57% | +2.42% | -8.77% | -1.26% | +3.03% | -2.94% | +0.92% | -0.35% | +0.31% | +1.76% | +2.12% | +2.50% | -1.89% | +0.24% | +3.81% | -1.16% | -0.49% | +2.88% | +1.86% | -1.11% | -4.33% | +1.87% | +61.67% | n/a |
Research and Development Revenue | 697.00M | 676.00M | 675.00M | 695.00M | 698.00M | 668.00M | 640.00M | 688.00M | 676.00M | 692.00M | 652.00M | 668.00M | 676.00M | 750.00M | 632.00M | 601.00M | 639.00M | 621.00M | 567.00M | 573.00M | 603.00M | 587.00M | 594.00M | 561.00M | 590.00M | 585.00M | 592.00M | 558.00M | 555.00M | 548.00M | 553.00M | 530.00M | 554.00M | 556.00M | 575.00M | 546.00M | 545.00M | 558.00M | 528.00M | 373.00M |
Research and Development Revenue Growth | +3.11% | +0.15% | -2.88% | -0.43% | +4.49% | +4.38% | -6.98% | +1.78% | -2.31% | +6.13% | -2.40% | -1.18% | -9.87% | +18.67% | +5.16% | -5.95% | +2.90% | +9.52% | -1.05% | -4.98% | +2.73% | -1.18% | +5.88% | -4.92% | +0.85% | -1.18% | +6.09% | +0.54% | +1.28% | -0.90% | +4.34% | -4.33% | -0.36% | -3.30% | +5.31% | +0.18% | -2.33% | +5.68% | +41.55% | n/a |